drugset / Trial / NCT02217332

Study of Dexpramipexole Chronic Sinusitis With Nasal Polyps and Eosinophilia

NCT02217332

Phase 2 Completed 20 enrolled Knopp Biosciences
NaSingle-groupOpen-labelTreatment

Summary

Phase 2, open-label, multi-center study to evaluate the clinical effects of oral administration of dexpramipexole for 6 months in subjects with chronic sinusitis with nasal polyps and eosinophilia.

Timeline

Start
2014-08
Primary completion
2016-12-14
Completion
2017-01-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexpramipexole Small molecule 150 mg Oral